Vectura Group announced that the company would be undergoing a $1.36 billion takeover by global investment firm The Carlyle Group.
Bristol-Myers Squibb’s shareholders voted to approve the drugmaker’s $74 billion takeover of Celgene despite a campaign by activist hedge fund Starboard Value LP to scuttle the deal.
U.S. generic drugmaker Akorn is taking former suitor Fresenius to court after the German healthcare group canceled their $4.75 billion takeover agreement.
Bayer might look into selling its animal health division if it continues to struggle to find takeover targets for the business, the German drugmaker’s incoming chief executive said.
Dublin, Ireland-based Perrigo Company plc (PRGO) announced today that it will take a number of actions, including layoffs, to increase profitability and help fend off a hostile takeover by Canonsburg, Penn. and UK-based Mylan N.V. The company plans to consolidate its global supply chain, operations and procurement management activities into a single global center […]
Generic and over-the-counter drugmaker Perrigo Co on Thursday urged its shareholders to reject Mylan NV’s unsolicited $27 billion tender offer, saying it substantially undervalued the company. Mylan first proposed to buy Perrigo in April and, after being repeatedly rebuffed, launched a tender offer on Monday. It has said it would take control if more than […]
Mylan NV on Monday officially took its takeover bid directly to shareholders of Perrigo Co. (PRGO 0.88 %) after the company’s board and management publicly rebuffed previous advances. Mylan is offering $75 in cash and 2.3 shares of Mylan for each Perrigo share held, valued at about $187 based on Friday’s closing price. Perrigo’s shares […]
Rival generic-drug makers Mylan NV and Perrigo Co. both chalked up wins this week in their hostile $36 billion takeover fight, which is heading into the homestretch. Mylan in April publicly bid for Perrigo, saying a combination would create a strong competitor in the quickly consolidating pharmaceuticals sector. Perrigo has rejected the price as too […]